Health Condition 1: D509- Iron deficiency anemia, unspecified
Conditions
Interventions
Intervention1: Intravenous iron ferric carboxymaltose will be given to 50 pregnant women with iron deficiency anaemia.: All 50 women will be given infusion of ferric carboxymaltose 750 mg in 250 ml of
Sponsors
DST Chandigarh
Eligibility
Inclusion criteria
Inclusion criteria: 1.Hemoglobin levels of >= 6 gm/dl - 9 gm/dl 2. Diagnosed case of Iron deficiency anemia. 3. Period of gestation between 20 to 36 weeks. 4. Singleton live pregnancy
Exclusion criteria
Exclusion criteria: 1.Anemia other than iron deficiency anemia. 2.Known serious hypersensitivity to other parenteral iron products. 3.Patients with known allergies including drug allergies, including patients with a history of severe asthma, eczema or other atopic allergy. 4.Patients with immune or inflammatory conditions (e.g. systemic lupus erythematosus, rheumatoid arthritis). 5.Chronic medical disorder 7.Antepartum hemorrhage 8.Anemia with heart failure 9. H/O Blood transfusion during current pregnancy. 11.COVID positive patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Increase in hemoglobin at 2 weeks, 6 weeks and at the time of delivery from the baseline hemoglobin. 2. Increase in serum ferritin levels at 2 and 6 weeks from baseline value. 3. Rise in reticulocyte count at 2 weeks. 4.Side effects of intravenous iron Carboxymaltose Timepoint: At 2 weeks,6 weeks and on the day of delivery. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood transfusion any time after complete dose of Intravenous ferric carboxymaltose injectionTimepoint: After complete dose of ferric carboxymaltose till delivery. | — |
Countries
India
Contacts
Public ContactDr Sunita Dubey
GMCH-Sector-32,Chandigarh
Outcome results
None listed